5-Ethyl-4-hydroxymethyl-2-methyl-pyridin-3-ol | 40519-63-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-Ethyl-4-hydroxymethyl-2-methyl-pyridin-3-ol
• 英文别名: 5-Ethyl-4-(hydroxymethyl)-2-methylpyridin-3-ol
• CAS: 40519-63-9
• 化学式: C₉H₁₃NO₂
• 分子量: 167.208
• InChiKey: NMGSTCZAHRSTPC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  53.4
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF UREA CYCLE DISORDERS AND HEPATIC DISEASES<br/>[FR] COMPOSITIONS ET MÉTHODES POUR LE TRAITEMENT D'ANOMALIES DU CYCLE DE L'URÉE ET DE MALADIES HÉPATIQUES
  申请人：RAO M SURYA

  公开号：WO2017090007A1

  公开（公告）日：2017-06-01

  The compositions and compounds of formula I, formula II, formula III which includes a molecular conjugate with ornithine or its polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection administration. Such compositions may be used to the treatment of urea cycle disorders and hepatic diseases or its associated complications.

  公式I、公式II、公式III的组合物和化合物包括与鸟氨酸或其多态体、对映体、立体异构体、溶剂合物和水合物形成的分子共轭物。这些盐可以制成药物组合物。药物组合物可以制成口服、颊粘膜、直肠、局部、经皮、经粘膜、静脉、肠道给药、糖浆或注射给药的制剂。这些组合物可以用于治疗尿素循环紊乱和肝脏疾病或其相关并发症。
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND INFLAMMATION<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR LE TRAITEMENT DE MALADIES NEUROLOGIQUES ET D'UNE INFLAMMATION
  申请人：KANDULA MAHESH

  公开号：WO2014115098A1

  公开（公告）日：2014-07-31

  The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I; and methods for treating or preventing neurological diseases and inflammation, a neurological disease, allergy, respiratory diseases or inflammatory disorder may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of muscle disorders, neurological diseases and inflammation, spasticity, neuropathic pain, fibromyalgia, Parkinson's disease, allergy, asthma, chronic obstructive pulmonary disease, allergic rhinitis, headache, chronic pain, sub-chronic pain and local pain or its associated complications.

  该发明涉及具有化学式I或其药用可接受的盐的化合物，以及其多型、溶剂合物、对映体、立体异构体和水合物。包括化学式I化合物的有效量的药物组合物；以及用于治疗或预防神经系统疾病和炎症、神经系统疾病、过敏、呼吸系统疾病或炎症性疾病的方法，可以制备用于口服、颊内、直肠、局部、经皮、经粘膜、静脉内、肠道、糖浆或注射的药物组合物。这些组合物可以用于治疗肌肉障碍、神经系统疾病和炎症、痉挛、神经病性疼痛、纤维肌痛、帕金森病、过敏、哮喘、慢性阻塞性肺病、过敏性鼻炎、头痛、慢性疼痛、亚慢性疼痛和局部疼痛或其相关并发症的治疗。
• SULFONYLETHYL PHOSPHORODIAMIDATES
  申请人：Allen R. David

  公开号：US20080039429A1

  公开（公告）日：2008-02-14

  Sulfonylethyl and thioethyl phosphorodiamidates, their preparation and intermediates in their preparation, formulations containing them, and their pharmaceutical use. The compounds are useful for treating cancer, alone and in combination with other anticancer therapies.

  Sulfonylethyl和thioethyl磷酰二胺酸酯，它们的制备及其制备中间体，含有它们的制剂，以及它们的药物用途。这些化合物可用于治疗癌症，单独或与其他抗癌疗法结合使用。
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES AND PRE-DIABETES
  申请人：Alapati Mohan Murali

  公开号：US20170073345A1

  公开（公告）日：2017-03-16

  The invention relates to the compounds and compositions of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprises a salt of dipeptidyl peptidase-4 inhibitor and the methods for treating or preventing metabolic syndrome, prediabetes and diabetes may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compounds and compositions may be used to treatment of diabetes mellitus, obesity, lipid disorders, hypertriglyceridemia, hyperglycemia, hyperinsulinemia and insulin resistance.
• US4144342A
  申请人：——

  公开号：US4144342A

  公开（公告）日：1979-03-13